je.st
news
Gilead's $1,000-a-pill hepatitis C drug may make financial sense for prisons
2014-10-21 15:36:50| Biotech - Topix.net
Sovaldi's $1,000-a-pill price has grabbed headlines, but a new study suggests it may actually be cost effective for prison systems. Pricey new hepatitis C drugs, such as Gilead Sciences Inc.'s Sovaldi, may make financial sense to give to give to prisoners, one of the main groups infected with the liver-damaging virus, according to a team of Stanford University researchers.
Tags: make
financial
sense
drug
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||